Verastem: Downgrading To Buy Based On RAMP-203 Setback In Targeting KRAS G12C NSCLC

2025-12-30 15:37:25 ET

The last time I wrote about Verastem, Inc. ( VSTM ) it was in a Seeking Alpha article entitled "Verastem: RAMP-203 Study Could Be Next Big Win For Avutometinib Combination." With respect to this article, I highlighted the opportunity that this company had in advancing the development of its oral RAF/MEK clamp avutometinib + G12C inhibitor LUMAKRAS [sotorasib] + oral FAK inhibitor defactinib as a triplet combination to treat patients with naive or previously treated with G12C inhibitor non-small cell lung cancer [NSCLC]. Plus, the doublet combination of only avutometinib + LUMAKRAS. This phase 1/2 RAMP-203 study was being conducted in collaboration with Amgen ( AMGN )....

Read the full article on Seeking Alpha

For further details see: